

Research Journal of Pharmaceutical, Biological and Chemical Sciences

Synthesis, Characterisation and Antibacterial Activity of some [8-Amino-4,7-dihydroxy-chromen-2-one] , [N-(3-Cyano-4-ethoxy-2-oxo-2H-chromen-7-yl)-formamide] Derivatives. The Comparison with Standard Drug

Aziz Behrami^{1*}, Kozata Vaso², Sevdie Govori³, Islam Krasniqi³, Skender Demaku³
Idreiz Vehapi³

^{1*}The Geoscience and Technology Faculty Material and Metallurgy Department- Mitrovica , University of Pristine ,Kosovo

²Department of Chemistry, Faculty of Natural Sciences, University of Tirana , Albania

³Department of Chemistry, University of Pristine , Kosovo

ABSTRACT

The present study deals with the synthesis , structure and antibacterial activity of [8-Amino-4,7-dihydroxy-chromen-2-one].[N-(3-Cyano-4-ethoxy-2-oxo-2H-chromen-7-yl)-formamide]. Derivatives are reported Compounds 2 - Chloro - 8- hydroxyl - 7-iminomethyl - 4H-1,5-dioxo-4-aza-phenanthrene-3,6-dione(**a**₁).N-(4-Ethoxy-3-formyl-2-oxo-2H-chromen-7-yl)-formamide(**b**₁).4-Ethoxy-7-formylamino-2-oxo-2H-chromene-3-carboxylic acid (2-chloro-8-hydroxy-3,6-dioxo-3,4-dihydro-2H,6H-1,5-dioxo-4-aza-phenanthren-7-ylmethyl)-amide(**c**). 4-Ethoxy-7-[3 - (4-methoxy - phenyl)-ureido]-2-oxo-2H-chromene-3-carboxylic acid [2-chloro - 8 - (4- methoxy - phenylamino)-3,6 - dioxo-3,4-dihydro-2 H,6H-1,5-dioxo-4-aza-phenanthren-7-ylmethyl]-amide(**d**).The structures of the synthesized compounds:(a₁,b₁,c,d) were characterized by spectroscopic methods,(IR, H¹-NMR , & C¹³-NMR) and analytical techniques (elemental analysis , melting point and TLC).The antibacterial activity of synthesized compounds was compared with antibacterial activity of the standard antibiotics cephalexine and streptomycin.The compounds shows different bacteriostatic and bactericidal activity against two cultures;Staphylococcus.aureus,Bacillus.cereus.

Keywords:[8-Amino-4,7-dihydroxy-chromen-2-one],Antibacterial activity,Staphylococcus aureus , Bacillus cereus,Cephalexine.

***Corresponding author:**

Email: a.behrami_chem@live.com

INTRODUCTION

Using [8-Amino-4,7-dihydroxy-chromen-2-one] (a), [N-(3-Cyano-4-ethoxy-2-oxo-2H-chromen-7-yl)-formamide] (b) as starting material, some new 2H-chromen-2-one (coumarin, 2H-1-benzopyran-2-one) derivatives (a_1), (b_1), (c), (d), are synthesized (**Schemes – I, II, III, IV**). 2H-Chromen-2-one derivative which are known as coumarin (specifically, a benzo- α -pyrone) derivatives are a large group of heterocyclic with oxygen as heteroatom [1-3]. Coumarin and its derivatives have biological activities [4-5]. Most of them show antibacterial, bactericidal and bacteriostatic properties [6-8]. Biological activity of coumarin derivatives is linked with their structure. The different substituent in the structure of benzo- α -pyrone or benzene of coumarin has different effect in biological activity [9].

Literature shows that the biological activity of coumarin derivatives is closely linked with their influence in enzymatic processes or has an analogy of their structure with the active enzymatic centres. But, it's very important to stress that a general correlation between the structure of coumarin derivatives and their microbiological activity it's not yet found, although many efforts made by different researches [10].

These wide ranges of biological properties [11,12] have stimulated us to synthesized some new coumarin derivatives, to find optimal method, optimal conditions of the synthesis and mechanism of reaction and to investigate their antibacterial activity against two bacterial cultures *Staphylococcus aureus*, *Bacillus cereus*.

The antibacterial activity of synthesized compounds were compared with antibacterial activity of streptomycin, and cephalaxine as standard antibiotics.

MATERIAL AND METHODS

Experimental

Compounds 2-Chloro-8-hydroxy-7-iminomethyl-4H-1,5-dioxo-4-aza-phenanthrene-3,6-dione (**a₁**), N-(4-Ethoxy-3-formyl-2-oxo-2H-chromen-7-yl)-formamide (**b₁**), 4-Ethoxy-7-formylamino-2-oxo-2H-chromene-3-carboxylic acid (2-chloro-8-hydroxy-3,6-dioxo-3,4-dihydro-2H,6H-1,5-dioxo-4-aza-phenanthren-7-ylmethyl)-amide (**c**), 4-Ethoxy-7-[3-(4-methoxyphenyl)-ureido]-2-oxo-2H-chromene-3-carboxylic acid [2-chloro-8-(4-methoxy-phenylamino)-3,6-dioxo-3,4-dihydro-4-aza-phenanthren-7-ylmethyl]-amide (**d**), are synthesized. The identification of 2H-chromen-2-one derivatives (a_1, b_1, c, d), is made by using melting point, infrared, ^1H NMR, ^{13}C NMR spectra and elemental analysis. Melting point was determined on a Electrothermal apparatus (Fisher Scientific 2555) in an open capillary tube and are uncorrected. Infrared spectra were recorded in cm^{-1} for KBr pellets on a FT-IR Shimadzu 8400S spectrophotometer with resolution 4 cm^{-1} . ^1H NMR spectra were recorded on a Bruker UNITY plus-500 'NMR 1' spectrometer using DMSO-d_6 as the solvent and TMS as the internal

references standard ($\sigma = 0,00$ ppm). Chemical shifts are expressed in δ ppm. Mass spectra were taken on a LKB 9000 mass spectrometer.

Element analysis was performed on a Perkin-Elmer 240 BCHN analyzer. The purity of the compounds (synthesized) was routinely checked by TLC using Merck Kieselgel-60 (F-254) and benzene, toluene, glacial acetic acid (80:10:10) as mobile phase. The spots were exposed in iodine vapour for visualization.

Synthesis of 2-Chloro-8-hydroxy-7-iminomethyl-4H-1,5-dioxo-4-aza-phenanthrene-3,6-dione (**a₁**) For this synthesis is used as substrate 8-Amino-4,7-dihydroxy-chromen-2-one in a 100 ml flask mixed 3 g of 8-Amino-4,7-dihydroxy-chromen-2-one (**a**) with 5 ml HCONH_2 , equivalent amount ClCH_2COCl and 0.3 ml triethylamine as catalyzer. The mixture was refluxed at 150°C for ca. 90 min. The obtained crystals yellow and orange are filtered and rinsed with ethanol and dried at room temperature. Recrystallization from absolute ethanol gave a yellow product of (**a₁**) compound at 80% yield, melting point 200°C . **Schemel**




Synthesis of N-(4-Ethoxy-3-formyl-2-oxo-2H-chromen-7-yl)-formamide (**b₁**) In a 100 ml flask were mixed 2.5 g of N-(3-Cyano-4-ethoxy-2-oxo-2H-chromen-7-yl)-formamide (**b**), with 5 ml Dioxane, 1 g SnCl_2 , 0.3 ml HCl . The mixture was refluxed at 80°C for ca. 1.5 h. The obtained yellow crystals are filtered and dried at room temperature. After obtained Aldimin added 2 ml H_2O . Then the reflux starts again for 30 min at 40°C . The obtained white crystals are filtered and dried at room temperature. Recrystallization from dioxane gave white crystals product of (**b₁**) compound at 70% yield, melting point, 157°C . **Schemell**


Synthesis of 4-Ethoxy-7-formylamino-2-oxo-2H-chromene-3-carboxylic acid (2-chloro-8-hydroxy-3,6-dioxo-3,4-dihydro-2H,6H-1,5-dioxo-4-aza-phenanthren-7-ylmethyl)amide (**c**) In a 100 ml flask were mixed 2 g 2-Chloro-8-hydroxy-7-iminomethyl-4H-1,5-dioxo-4-aza-phenanthrene-3,6-dione (**a₁**), N-(4-Ethoxy-3-formyl-2-oxo-2H-chromen-7-yl)-formamide (**b₁**), with 10 ml ethanol, 0.3 ml HCl , 0.3 ml Et_3N as catalyzer. The mixture was refluxed at 92°C in water bath for ca. 7 h. The flask was placed in an ice bath for 1 h until yellow crystalline precipitate was formed. After filtration the product was recrystallized from ethanol.

The recrystallization from ethanol gave a yellow product of (**c**) compound at 70% yield, melting point, 180°C . **Schemelll**


Synthesis of 4-Ethoxy-7-[3-(4-methoxy-phenyl)-ureido]-2-oxo-2H-chromene-3-carboxylic acid [2-chloro-8-(4-methoxy-phenylamino)-3,6-dioxo-3,4-dihydro-2H,6H-1,5-dioxo-4-aza-phenanthren-7-ylmethyl]-amide (**d**) in a 100 ml of flask were mixed 1.5 g of 4-Ethoxy-7-formylamino-2-oxo-2H-chromene-3-carboxylic acid (2-chloro-8-hydroxy-3,6-dioxo-3,4-dihydro-2H,6H-1,5-dioxo-4-aza-phenanthren-7-ylmethyl)-amide (**c**), 1.5 g $\text{C}_7\text{H}_9\text{NO}$ (Anisidine) with 7 ml CH_3CN (Acetonitrile), 0.3 ml Et_3N . The mixture was refluxed at 95°C in water bath for ca. 5 h. The obtained violet crystals are filtered and rinsed with CH_3CN and dried at room

temperature. Recrystallization from ethanol gave a violet product of **(d)** product at 60% yield, melting point 186°C. **Scheme IV.**

Scheme I

Scheme II

Scheme III




4-Ethoxy-7-formylamino-2-oxo-2H-chromene-3-carboxylic acid (2-chloro-8-hydroxy-3,6-dioxo-3,4-dihydro-2H,6H-1,5-dioxo-4-aza-phenanthren-7-ylmethyl)-amide



4-Ethoxy-7-[3-(4-methoxy-phenyl)-ureido]-2-oxo-2H-chromene-3-carboxylic acid [2-chloro-8-(4-methoxy-phenylamino)-3,6-dioxo-3,4-dihydro-2H,6H-1,5-dioxo-4-aza-phenanthren-7-ylmethyl]-amide

Antibacterial activity

The purified synthesized compounds (a_1 , b_1 , c, d) was subjected to test in vitro its antibacterial activity against two bacterial cultures ; Staphylococcus aureus , Bacillus cerues . Antibacterial activity of compounds was investigated applying the Kirby-Bayer method¹⁴ or disc method (d=5.5 mm max. capacity 10 μ g)

Table 1 Antibacterial activity- Staphylococcus aureus Inhibition zone (mm)

Compound	2mg/ml	3mg /ml	5mg/ml
a_1	13	19	21
b_1	6	9	11
C	6	9	12
D	10	13	18
Cephalexine	7	7	7 10 μ g
Streptomycine	20	20	20 10 μ g

Table 2 Antibacterial activity - Bacillus cereus Inhibition zone (mm)

Compound	2mg/ml	3mg /ml	5mg/ml
a ₁	14	19	20
b ₁	10	13	17
C	12	15	18
D	11	18	21
Cephalexine	9	9	9 10 µg
Streptomycine	23	23	23 10 µg

Table 3

Compound	IR (cm ⁻¹)	¹ H NMR ppm	¹³ C NMR ppm
a ₁	3450(OH),3330 (NHCO), 1740(C=O),1680(CH=NH), 1660(NHCO),1600(C=C)Ar 1040(C-O-C),657(C-Cl)	δ.6.22 (s,H,CHCl) 6.7,7.3 (d,2H,Ar) 7.50(s,H,CH=NH) 8.0(s,H,NH) 11.0(s,H,OH)	δ.111,119,120,123,(C,Ar) 82(CH ₂),105(CHCl) 153(C,CO),162(C,COO) 163(C,CO-NH) 163.7(C,CH=NH) 173(C,CH-OH)
b ₁	3220(NHCO),2850(C-H) 2720(CHO),1728(C=O) 1700(CHO),1620(NHCO) 1600(C=C)Ar,1100(C-O)	δ.1.0,1.17,1.22(t,3H,CH ₃) 3.98,4.0,(d,2,HOCH ₂) 4.1,(s,H,NH) 7.60,7.61,7.58(m,3H,Ar) 8.21,8.23,(d,H,HCONH) 9.68,(s,H,CHO)	δ.15.1,(C,CH ₃),60,(C,CH ₂ O) 97.1,(C,=C=CH) 113,117,126,123(C,Ar) 137,(C,CNH),57(C,C=O) 162(C,COO),190(C,CHO)
C	3400(OH),3372(NH) 3200(NHCO),2830(C-H) 2720(CHO),1732(C=O) 1718(CHO),1628(NHCO) 1620(NHCO),1600(NHCO) 1073(NH-C),1050(C-O) 732(C=C)618(C-Cl)	δ.1.07,1.20(d,3H,CH ₃) 2.50,3.63(m,H,N-CH ₂) 3.76(d,H,O-CH ₂),4(sH,NH) 6.62(s,H,CHCl),6,7- 7.60(m,5H,Ar).8.29- 8.51(m,3H,NHC=O) 9.09-9.91(d,H,CHO) 10.84(s.H.OH)	δ.15.1(C,CH ₃),59.7(C,OCH ₂) 35.0(c,CH ₂ NH),92(c,=C- CH ₂),111,113,117,120,123,126 (6C,Ar),105(C-Cl) 119(C-N) 153(C,CO),162(C,COO) 160.5(C,CONH), 163,2(C,CONH) 166.8(C,CONH) 180.2(C,C-O)
D	3350(NHCO),3200(NHC) 1720(C=O),1620, 1615(NHCO),1600(C=C) 1250,1050(C-O) 780(C=C)Ar,620(C-Cl)	δ.0.9,1.17,1.25(t,3H,CH ₃) 2.27-2.74(m,2H-CH ₂ NH) 3.08-3.63(m,H,nHCH ₂) 3,73,3,75(d,6H,2OCH ₃) 3.78,3.80,3,81(t,H,NH) 4.0(s,2H,OCH ₂) 5.65,5.95(d,2H,2NHCO) 6.35-7.65(m,9H,Ar) 8.23-8.41(d,2H.NHCO)	δ.15(C,CH ₃),36.4(C,CH ₂ NH) 56(C,OCH ₃),59.7(C,OCH ₂) 105.6(C,CHCl),111,113,114.9, 114,116,117,120,(11C,Ar) 119.2(C,C-NH),139(C,C-NH) 143.7(C-O),152.2(C,CONH) 162(C,COO),162.3(C,CONH) 166.8(C,CONH)

Table-4 Analytical data

Compd	Yield (%)	m.p	M.F	Elemental analysis.Calculated (found) (%)				
				C	H	N	O	Cl
a ₁	80	200	C ₁₂ H ₇ ClN ₂ O ₅	48.92 (48.37)	2.39 (2.29)	9.51 (9.30)	27.15 (26.80)	12.03 (11.94)
b ₁	70	157	C ₁₃ H ₁₁ NO ₅	59.77 (59.0)	4.24 (3.90)	5.36 (4.90)	30.62 (29.0)	
C	80	180	C ₂₅ H ₁₈ ClN ₃ O ₁₀	54.02 (54.0)	3.26 (2.95)	7.56 (7.50)	28.78 (28.70)	6.38 (6.30)
D	60	186	C ₃₉ H ₃₂ ClN ₅ O ₁₁	59.89 (59.0)	4.12 (4.00)	8.95 (8.80)	22.50 (21.80)	4.53 (3.90)

CONCLUSION

From the results the following conclusion were drawn: The study provides the first evidence that compounds (a₁, b₁, c, d) obviously inhibit the growth of *Staphylococcus aureus* and *Bacillus cereus*.

Antibacterial activity of a₁, b₁, c, d compounds is stronger than of Cephalexine in *S. aureus* and *B. cereus*. The compounds a₁, b₁, c, d compared with the antibacterial activity of Streptomycin in *S. aureus* and *B. cereus*.

The chemical structures of synthesized compounds were determined according to extensive NMR experiments and published data.

ACKNOWLEDGEMENTS

The authors thank Prof. Branko Stanovnik, University of Ljubljana and its laboratory staff for ¹H NMR spectrum and elemental analyses.

REFERENCES

- [1] SGovori, V Kalaj, VRapic, LKalaj and SDakovic. *Heterocycl Commun* 2002; 8: 129.
- [2] B Stanovnik, H Susachitzky and EF Scriven. *Progress in Heterocyclic Chemistry*. 1993; 5: 75-146.
- [3] SHLee, DSShin, JSKim, KB Oh and SSKan. *Arch Pharm Res* 2003; 26.
- [4] KBVyas, KS Nimavat, GRJani and MV Hathi. *Orbital* 2009; 1: 183.
- [5] AZ Aбыshev, VAGimdein, EV Semenov, EMEMAgev, AA Abdulla Zade and AB Gueseinov. *Pharm Chem J* 40: 607 (2206).
- [6] ABehrami, KVaso, IKrasniqi. *J Int Environ Appl Sci* 2010; 5: 247.
- [7] MD Aytemir, RC Hider, DD Erol, M Ozalp and M Ekizoglu. *Turk J Chem* 2003; 27: 445.
- [8] MM El Saghier, MB Naili, BKhrammash, NA Saleh and KM Kreddan. *Arkivoc* 83; 2007.
- [9] ZMNofal, M El-Zahar and S Abd El Karim. *Molecules* 2000; 5: 99.
- [10] Chaluvvaraju KC and Ishwarbhat K. *Asian J Chem* 2008; 20: 4335.



ISSN: 0975-8585

- [11] Rajan Ra Kali, Jubie S, Grworamma B and Suresh B. Asian J Chem 2008; 20: 5289.
- [12] Ali Mohammed Ashraf and Sharayar Mohammed. Boorg Med ChemLett 2009; 17: 3314.